Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy

Figure 1

Inhibition of GSK-3 decreases proliferation and clonogenic survival of pancreatic cancer cells in a dose- and time-dependent manner. A. Effects of AR-18 (μM) on the growth inhibition of BxPC-3 and PANC-1 cells after 24, 48, and 72 h of drug exposure measured by SRB assay. Each point signifies mean from three experiments, each including six replicates; error bars = ± SEM. The results are relative to untreated control. B. Growth inhibitory effect of AR-18 (μM) against six pancreatic cancer cell lines after exposure for 24, 48, and 72 h, measured by SRB assay. Each point signifies mean from three separate experiments, each including six replicates; error bars = ± SEM. The results are relative to untreated control. C. Effects of AR-18 on the number of colony-forming PANC-1 and BxPC-3 cells after drug exposure for 24 h. Control cells were given vehicle solution. Each point represents mean for four experiments, each containing three replicates; error bars = ± SEM. The results are relative to untreated control.

Back to article page
\